Top
Summary
All studies
Mortality
ICU
Serious outcomes
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
Top
All levilimab studies
 
Feedback
Home
c19early.org COVID-19 treatment researchLevilimabLevilimab (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 levilimab studies

Home
Post
Share
@CovidAnalysis
StudiesStudies
FeedbackFeedback
All studies   Mortality   ICU   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies 0% 1 206 Improvement, Studies, Patients Relative Risk Mortality 0% 1 206 ICU admission 70% 1 206 RCTs 0% 1 206 Late 0% 1 206 Levilimab for COVID-19 c19early.org October 2024 Favorslevilimab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CORONA Lomakin (DB RCT) 0% 1.00 [0.26-3.89] death 4/103 4/103 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 1. Late treatment 0% 1.00 [0.26-3.89] 4/103 4/103 no change All studies 0% 1.00 [0.26-3.89] 4/103 4/103 no change 1 levilimab COVID-19 study c19early.org October 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors levilimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CORONA Lomakin (DB RCT) 0% 1.00 [0.26-3.89] 4/103 4/103 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 1. Late treatment 0% 1.00 [0.26-3.89] 4/103 4/103 no change All studies 0% 1.00 [0.26-3.89] 4/103 4/103 no change 1 levilimab COVID-19 mortality result c19early.org October 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 1. Favors levilimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CORONA Lomakin (DB RCT) 70% 0.30 [0.09-1.06] 3/103 10/103 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.061 Late treatment 70% 0.30 [0.09-1.06] 3/103 10/103 70% lower risk All studies 70% 0.30 [0.09-1.06] 3/103 10/103 70% lower risk 1 levilimab COVID-19 ICU result c19early.org October 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.061 Favors levilimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CORONA Lomakin (DB RCT) 0% 1.00 [0.26-3.89] death 4/103 4/103 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 1. Late treatment 0% 1.00 [0.26-3.89] 4/103 4/103 no change All studies 0% 1.00 [0.26-3.89] 4/103 4/103 no change 1 levilimab COVID-19 serious outcome c19early.org October 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors levilimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CORONA Lomakin (DB RCT) 0% 1.00 [0.26-3.89] death 4/103 4/103 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 1. Late treatment 0% 1.00 [0.26-3.89] 4/103 4/103 no change All studies 0% 1.00 [0.26-3.89] 4/103 4/103 no change 1 levilimab COVID-19 Randomized Controlled Trials c19early.org October 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors levilimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CORONA Lomakin (DB RCT) 0% 1.00 [0.26-3.89] 4/103 4/103 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 1. Late treatment 0% 1.00 [0.26-3.89] 4/103 4/103 no change All studies 0% 1.00 [0.26-3.89] 4/103 4/103 no change 1 levilimab COVID-19 RCT mortality result c19early.org October 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 1. Favors levilimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CORONA Lomakin (DB RCT) 0% 1.00 [0.26-3.89] death 4/103 4/103 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 1. Late treatment 0% 1.00 [0.26-3.89] 4/103 4/103 no change All studies 0% 1.00 [0.26-3.89] 4/103 4/103 no change 1 levilimab COVID-19 peer reviewed studies c19early.org October 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors levilimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CORONA Lomakin (DB RCT) 0% 1.00 [0.26-3.89] death 4/103 4/103 Improvement, RR [CI] Treatment Control CORONA Lomakin (DB RCT) 70% 0.30 [0.09-1.06] ICU 3/103 10/103 CORONA Lomakin (DB RCT) 65% 0.35 [0.21-0.57] no improv. 16/103 46/103 Levilimab COVID-19 outcomes c19early.org October 2024 Favors levilimab Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0